For both injection and tablet formulations, a gradual doseescalation schedule over approximately 16 weeks (injection) or 90 days (tablets) is standard to improve GI tolerability. For prescribers , key considerations include: Confirming that the intended use is FDAapproved (CV risk reduction, chronic weight management, or adult MASH with F2F3 fibrosis) and that BMI and comorbidity criteria are met. Excluding contraindications (MTC/MEN 2, prior anaphylaxis/angioedema to semaglutide) and identifying risk factors such as prior pancreatitis, gallbladder disease, severe GI motility disorders, and advanced diabetic retinopathy
Kim JS, Jegal KH, Park HR, Choi BR, Kim JK, Ku SK
Send this story to a friend
Mystery behind labial and oral melanotic macules: Clinical, dermoscopic and pathological aspects of Laugier-Hunziker syndrome
When both factors combine, gastrointestinal symptoms may be more pronounced